Schedule 13D ownership disclosure
PROVECTUS PHARMACEUTICAL INCORPORATED
Common Stock, par value $0.001 per share · CUSIP: 74373P108
Event date: 2025-11-26
- Filing-level shares
- 49,255,894.00
- Percent of class
- 10.56%
- Pershing EdwardReported CIK 0001689739
Shares: 49,255,894.00 · Class: 10.56%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001493152-25-025639
- Form type
- SCHEDULE 13D/A
- Filer
- PROVECTUS BIOPHARMACEUTICALS, INC.
- CIK
- CIK 315545
- Filed
- Dec 01, 2025
- Reporting period
- Nov 26, 2025
- Description
- Schedule 13D beneficial ownership